SecSonar.com

NovaBridge Biosciences (NBP)

NovaBridge Biosciences at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

NovaBridge Biosciences (NBP) is a Biotechnology company based in US with a market capitalization of $213.2M. Free cash flow was negative at -$20.6M. This page tracks NBP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 32 employees · IPO Jan 17, 2020

Valuation

Valuation & price

$1.82 · as of May 17, 2026 · -72.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

6.46

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.56$4.01$1.47Jul 25Dec 25Jul 26Jul 7, 25$2.09Jul 9, 25$2.31Jul 11, 25$2.13Jul 15, 25$2.10Jul 17, 25$2.16Jul 21, 25$2.12Jul 23, 25$2.11Jul 25, 25$2.11Jul 29, 25$1.70Jul 31, 25$2.01Aug 4, 25$2.93Aug 6, 25$3.74Aug 11, 25$3.89Aug 13, 25$4.24Aug 15, 25$4.87Aug 19, 25$4.21Aug 21, 25$4.71Aug 25, 25$4.82Aug 27, 25$4.50Aug 29, 25$4.16Sep 3, 25$4.65Sep 5, 25$4.38Sep 9, 25$4.60Sep 11, 25$3.90Sep 16, 25$3.72Sep 18, 25$3.65Sep 22, 25$3.88Sep 24, 25$3.56Sep 26, 25$3.48Sep 30, 25$3.78Oct 2, 25$4.13Oct 6, 25$4.35Oct 8, 25$5.07Oct 10, 25$4.77Oct 14, 25$6.06Oct 16, 25$6.56Oct 21, 25$5.13Oct 23, 25$4.39Oct 27, 25$4.70Oct 29, 25$4.63Oct 31, 25$4.95Nov 4, 25$4.27Nov 6, 25$4.19Nov 10, 25$4.29Nov 12, 25$4.22Nov 14, 25$4.15Nov 18, 25$4.54Nov 20, 25$4.19Nov 25, 25$3.90Nov 28, 25$3.84Dec 2, 25$3.68Dec 4, 25$3.99Dec 8, 25$4.02Dec 10, 25$4.09Dec 12, 25$3.99Dec 16, 25$4.21Dec 18, 25$3.96Dec 22, 25$4.39Dec 24, 25$4.63Dec 29, 25$4.03Jan 2, 26$4.27Jan 6, 26$3.88Jan 8, 26$3.79Jan 12, 26$3.72Jan 14, 26$3.53Jan 16, 26$3.73Jan 21, 26$3.79Jan 23, 26$3.89Jan 27, 26$3.98Jan 29, 26$3.68Feb 2, 26$3.43Feb 4, 26$3.42Feb 9, 26$3.47Feb 11, 26$3.39Feb 13, 26$3.21Feb 18, 26$3.29Feb 20, 26$3.29Feb 24, 26$3.25Feb 26, 26$3.28Mar 2, 26$3.45Mar 4, 26$3.11Mar 6, 26$3.50Mar 10, 26$3.24Mar 12, 26$2.94Mar 17, 26$2.88Mar 19, 26$2.69Mar 23, 26$2.63Mar 25, 26$2.64Mar 27, 26$2.54Mar 31, 26$2.46Apr 2, 26$2.43Apr 7, 26$2.48Apr 9, 26$2.43Apr 13, 26$2.40Apr 15, 26$2.60Apr 17, 26$2.70Apr 22, 26$2.58Apr 24, 26$2.45Apr 28, 26$2.39Apr 30, 26$2.47May 4, 26$2.40May 6, 26$2.25May 8, 26$2.20May 12, 26$2.06May 14, 26$1.92May 18, 26$1.71May 20, 26$1.76May 22, 26$1.77May 28, 26$1.87Jun 1, 26$1.71Jun 3, 26$1.75Jun 5, 26$1.65Jun 9, 26$1.59Jun 11, 26$1.47Jun 15, 26$1.47Jun 17, 26$1.57Jun 22, 26$1.53Jun 24, 26$1.60Jun 26, 26$1.64Jul 2, 26$2.14
$1.4752-week range$6.56
Loading valuation history…

Fundamentals

Key fundamentals

$213.2M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$20.6M

Free cash flow (USD)

-$29.7M

Net debt

Net cash position

-48.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$11.6MFY 2018$53.8MFY 2019$30.0MFY 2020$1.5BFY 2021$88.0MFY 2022$-10.7MFY 2023$4.5MFY 2024$0.00FY 2025$0.00
$11.6M$0

Free cash flow by year

2017 → 2025

FY 2017$-272.5MFY 2018$-295.1MFY 2019$-880.2MFY 2020$425.6MFY 2021$-1.0BFY 2022$-1.1BFY 2023$-73.0MFY 2024$-52.7MFY 2025$-20.6M
-$272.5M-$20.6M

Gross margin by year

2021 → 2023

FY 202147.3%FY 20222325.8%FY 2023100.0%
47.3%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 20-F/A filed Jun 16, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingManagement ChangeJun 29, 2026Filing
  • Insider sellInsider Sell $6KDennis Phillip Andrew · Chief Medical Officer · $5.6KJun 22, 2026Filing
  • 6-K filingFDA Fast Track DesignationJun 16, 2026Filing
  • 6-K filingChange of AccountantsJun 16, 2026Filing
  • Annual report20-F FiledJun 16, 2026Filing
  • 6-K filingManagement ChangeApr 22, 2026Filing
  • Annual reportAnnual Report FiledApr 7, 2026Filing
  • Annual report20-F FiledApr 7, 2026Filing

Questions

Frequently asked questions

What is NovaBridge Biosciences's market cap?

NovaBridge Biosciences (NBP) has a market capitalization of $213.2M.

What is NBP's P/E ratio?

A meaningful P/E ratio is not available for NBP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NBP's price-to-book (P/B) ratio?

NBP trades at 6.46 times book value per share.

Are insiders buying NBP stock?

SEC Form 4 filings show no open-market insider buys at NovaBridge Biosciences in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

RNAC

Cartesian Therapeutics, Inc.

$212.4M

PRLD

Prelude Therapeutics Incorporated

$218.6M

IPSC

Century Therapeutics, Inc.

$205.2M

HUMA

Humacyte, Inc.

$222.6M

YDES

YD Bio Limited Ordinary Shares

$223.1M

SLGL

Sol-Gel Technologies Ltd.

$225.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.